中生北控BioSino品牌怎么样 申请店铺

我要投票 中生北控BioSino在基因检测行业中的票数:223 更新时间:2025-04-27
中生北控BioSino是哪个国家的品牌?「中生北控BioSino」是 中生北控生物科技股份有限公司 旗下著名品牌。该品牌发源于北京市,由创始人陈 * 添在1988年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力中生北控BioSino品牌出海!通过在本页面挂载中生北控BioSino品牌的产品链接和联系方式,可以提高中生北控BioSino产品曝光!跨境电商爆单神器,目前只要100元/年哦~

中生北控BioSino怎么样

二十世纪七十年代初,中国科学院生物物理研究所主持承担国家824任务,成功的人工合成了酵母丙氨酸转移核糖核酸。为此,生物物理研究所科技人员组建了工具酶研制组,作为国内生命科学领域高水平的研究基地之一,这只科研队伍研制并生产出主要性能指标达到国外同类水平的酶法临床化学检验试剂。随着科研成果转化规模的不断扩大,为满足市场的迫切需要,生物物理所投资成立了中生生化试剂技术开发公司,就此拉开中国生化诊断试剂产业发展的序幕。经过四十五年的成长与蜕变,成为今天的中生北控生物科技股份有限公司。

中生北控生物科技股份有限公司是中国科学院生物物理研究所创办并控股的高新技术企业,以蛋白质产业为主业,主要从事体外诊断产品的研发、生产和销售。自1973年建厂到1988年公司成立以来,始终以满足民生需求为导向,积极推动民族IVD产业的发展,打造产、学、研、用相结合的自主创新体系,探索“国际化、集团化、复合化”的经营模式,构建“系统化、系列化、整体化、智能化”四化一体的全产业链,提升核心竞争力,在行业中处于重要地位。

中生北控公司自研发和生产“酶法诊断单、双试剂”系列产品以来,经过四十五年的发展,建立了完整的生化检测系列产品平台,发展了免疫诊断系列产品、分子诊断系列产品、血球诊断系列产品、医用临床营养诊断系列产品等。公司拥有包括由8位博士、33位硕士组成的能力过硬的科研团队,拥有由国家人事部批准设立的“企业博士后科研工作站”,与国内生命科学领域高水平的科研机构联建的体外诊断工程研究中心,并与国际知名企业开展合作。

中生北控公司根植于中国科学院这片知识创新的沃土,秉承“做诚信人、为天下先”的企业价值观,拥有16000平方米严格按照GMP标准建设的生产基地,产品质量通过了ISO13485体系认证,质量管理和质量控制水平通过ISO/ICE17025:2005《检验与校准实验室能力的通用要求》的认可,获得使用CNAS实验室认可标志。公司在国内拥有500多家代理商和销售商,在全国大部分的省份和海外都设有分支机构,建立了覆盖全国的市场营销网络及技术支持与技术服务体系。



In the early 1970s, the Institute of Biophysics, Chinese Academy of Sciences, took charge of the national 824 task and successfully synthesized yeast alanine tRNA. For this reason, the scientific and technological personnel of the Institute of Biophysics have set up a tool enzyme research group, which is one of the high-level research bases in the field of life science in China. This research team has developed and produced the enzyme clinical chemical test reagents whose main performance indexes reach the same level in foreign countries. With the continuous expansion of the transformation scale of scientific research achievements, in order to meet the urgent needs of the market, the Institute of biophysics has invested in the establishment of the Zhongsheng biochemical reagent technology development company, which has opened the prelude to the development of China's biochemical diagnostic reagent industry. After 45 years of growth and transformation, it has become today's Zhongsheng Beikong Biotechnology Co., Ltd. Zhongsheng Beikong Biotechnology Co., Ltd. is a high-tech enterprise established and controlled by the Institute of Biophysics, Chinese Academy of Sciences. Its main business is protein industry, mainly engaged in the research, development, production and sales of in vitro diagnostic products. Since its establishment in 1973 and its establishment in 1988, the company has always been oriented to meet the needs of the people's livelihood, actively promoting the development of national IVD industry, building an independent innovation system combining production, learning, research and use, exploring the business model of "internationalization, collectivization and compounding", building a whole industrial chain of "systematization, seriation, integration and intelligence", and improving the core Competitiveness, in the industry in an important position. Since the R & D and production of "enzyme diagnosis single and double reagents" series products, after 45 years of development, the company has established a complete biochemical detection series product platform, developed immune diagnosis series products, molecular diagnosis series products, blood cell diagnosis series products, medical clinical nutrition diagnosis series products, etc. The company has an excellent research team composed of 8 doctors and 33 masters, an "enterprise postdoctoral research workstation" approved by the Ministry of human resources of the people's Republic of China, an in vitro diagnostic engineering research center jointly established with domestic high-level scientific research institutions in the field of life sciences, and cooperates with internationally renowned enterprises. Zhongsheng Beikong company is rooted in the fertile land of knowledge innovation of the Chinese Academy of Sciences. It adheres to the enterprise values of "being honest, being the first in the world". It has a 16000 square meter production base built in strict accordance with GMP standards. Its product quality has passed the ISO13485 system certification. Its quality management and quality control level have passed the general requirements for the ability of inspection and calibration laboratories (ISO / ice17025:2005) The CNAs laboratory approval mark is obtained. The company has more than 500 agents and distributors in China, branches in most provinces and overseas, and established a nationwide marketing network, technical support and technical service system.

本文链接: https://brand.waitui.com/20a181997.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

视源股份:2024年营收224.01亿元,同比增长11%

36氪获悉,视源股份(002841.SZ)同步披露了2024年年报和2025年一季报,业绩增长稳健。2024年视源股份实现营业收入224.01亿元,同比增长11%,创历史新高;归属于母公司股东的净利润9.71亿元。2024年公司全年海外收入达到43.5亿元,同比增长16.83%。2024年智能控制部件业务营收首次突破100亿元,达102.74亿元,同比增长20.37%。2025年第一季度延续稳健增长态势,公司实现营业收入50.05亿元,同比增长11.35%。同时,视源股份已宣布正式启动港股上市计划。

2小时前

受特朗普关税影响 IDC预计2025年全球IT支出增长率将从10%降至5%

据日经中文,美国特朗普政府的关税政策正在成为高科技产业的逆风,如果将税率上升部分转嫁到价格上,那么智能手机、个人电脑、服务器等多种产品的需求将下降。调查公司IDC预计,2025年全球IT支出增长率将从同比增长10%降至同比增长5%。此前,IDC预计2025年的IT支出规模为4.1万亿美元,同比增长10%。(财联社)

2小时前

宝马中国宣布接入DeepSeek

继与阿里巴巴达成AI大语言模型战略合作后,宝马再度深化本土AI生态布局,宝马中国宣布接入DeepSeek。未来,DeepSeek功能也将应用于国产宝马新世代车型。今年三季度开始,将率先应用于多款搭载第9代(BMW)操作系统的中国在售新车,通过深度思考能力赋能以BMW智能个人助理为中心的人机交互体验。(财联社)

2小时前

“五一”假期民航旅客运输量预计1075万人次 ,创同期历史新高

民航局发布“五一”假期民航运输保障安排。民航局运输司副司长商可佳介绍,“五一”假期是旅游休闲、探亲访友的出行高峰期,民航运输市场将保持平稳增长态势。今年“五一”假期共计5天,根据预测,民航旅客运输量约为1075万人次,日均215万,同比2024年增长8%,创同期历史新高。假期首末的单日客流峰值有望突破230万人次。(中国民航报)

2小时前

飞天茅台价涨 今日25年飞天原箱批价报2150元/瓶

今日酒价披露的批发参考价显示,4月27日,25年飞天茅台原箱较前一日上涨15元,报2150元/瓶。24年飞天茅台原箱较前一日上涨20元,报2160元/瓶;24年飞天茅台散瓶较前一日上涨10元,报2100元/瓶。(财联社)

2小时前

本页详细列出关于中生北控BioSino的品牌信息,含品牌所属公司介绍,中生北控BioSino所处行业的品牌地位及优势。
咨询